Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 8/20 | 0.51 |
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.51 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.41 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3931967 | 1.00 | CHRM3 (0.51) | CHRM3CHRM2FPR2DRD2DRD4 | |
| Bromide SCHEMBL5198499 | 0.80 | HSD11B1 (0.42) | CHRM3CHRM2DRD2OPRM1 | |
| Bromide SCHEMBL5198501 | 0.80 | HSD11B1 (0.42) | CHRM3CHRM2DRD2OPRM1 | |
| SCHEMBL3941523 | 0.79 | FPR2 (0.56) | CHRM3CHRM2FPR2DRD2DRD4 | |
| SCHEMBL13898835 | 0.79 | CHRM3 (0.56) | CHRM3CHRM2FPR2DRD2DRD4 | |
| SCHEMBL13899122 | 0.79 | FPR2 (0.56) | CHRM3CHRM2FPR2DRD2DRD4 | |
| SCHEMBL3939716 | 0.79 | FPR2 (0.56) | CHRM3CHRM2FPR2DRD2DRD4 | |
| Bromide SCHEMBL8563395 | 0.77 | HDAC1 (0.43) | CYP2D6CYP2C19 | |
| Bromide SCHEMBL8563399 | 0.77 | HDAC1 (0.43) | CYP2D6CYP2C19 | |
| SCHEMBL6384049 | 0.76 | CHRM3 (0.53) | CHRM3CHRM2FPR2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311518-B1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2005-11-02 | — | — | EP | claimed |
| US-6828442-B2 | Coupling N-benzyl-3-pyrrolidinamine compound with acyl halide; cyclization in presence of a base; reacting with triphenylphosphine to obtain phosphonium salt; reacting with di-tert. -butyl-dicarbonate under hydrogenation conditions | BASILEA PHARMACEUTICA AG (CH) | 2004-12-07 | — | — | US | claimed |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-16 | — | — | US | claimed |
| EP-1311518-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | Basilea Pharmaceutica AG (CH) | 2003-05-21 | — | — | EP | claimed |
| WO-2002014332-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2002-02-21 | — | — | WO | claimed |
| US-7511154-B2 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICALS AG (CH) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PHOSPHO1, PTMS | CHRM3 3163/4885CHRM2 3132/4885OPRM1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.